全文获取类型
收费全文 | 34958篇 |
免费 | 2311篇 |
国内免费 | 98篇 |
专业分类
耳鼻咽喉 | 584篇 |
儿科学 | 852篇 |
妇产科学 | 541篇 |
基础医学 | 5109篇 |
口腔科学 | 626篇 |
临床医学 | 3315篇 |
内科学 | 7412篇 |
皮肤病学 | 750篇 |
神经病学 | 3461篇 |
特种医学 | 1596篇 |
外国民族医学 | 22篇 |
外科学 | 5263篇 |
综合类 | 223篇 |
一般理论 | 11篇 |
预防医学 | 2173篇 |
眼科学 | 930篇 |
药学 | 2290篇 |
中国医学 | 55篇 |
肿瘤学 | 2154篇 |
出版年
2023年 | 190篇 |
2022年 | 353篇 |
2021年 | 931篇 |
2020年 | 522篇 |
2019年 | 780篇 |
2018年 | 938篇 |
2017年 | 642篇 |
2016年 | 735篇 |
2015年 | 864篇 |
2014年 | 1125篇 |
2013年 | 1461篇 |
2012年 | 2151篇 |
2011年 | 2121篇 |
2010年 | 1197篇 |
2009年 | 1105篇 |
2008年 | 1745篇 |
2007年 | 1785篇 |
2006年 | 1602篇 |
2005年 | 1543篇 |
2004年 | 1399篇 |
2003年 | 1223篇 |
2002年 | 1205篇 |
2001年 | 802篇 |
2000年 | 817篇 |
1999年 | 710篇 |
1998年 | 337篇 |
1997年 | 295篇 |
1996年 | 259篇 |
1995年 | 226篇 |
1994年 | 197篇 |
1993年 | 169篇 |
1992年 | 470篇 |
1991年 | 493篇 |
1990年 | 467篇 |
1989年 | 419篇 |
1988年 | 423篇 |
1987年 | 377篇 |
1986年 | 376篇 |
1985年 | 323篇 |
1984年 | 267篇 |
1983年 | 211篇 |
1982年 | 169篇 |
1979年 | 240篇 |
1978年 | 181篇 |
1977年 | 177篇 |
1976年 | 157篇 |
1975年 | 159篇 |
1974年 | 190篇 |
1973年 | 154篇 |
1972年 | 159篇 |
排序方式: 共有10000条查询结果,搜索用时 631 毫秒
151.
C. Sohy F. Pons A. Casset M.-P. Chesnard F. Lieutier-Colas P. Meyer G. Pauli F. de Blay 《Clinical and experimental allergy》2006,36(6):795-802
BACKGROUND: Endotoxin was proposed to increase the severity of asthma. Endotoxin levels greatly differ according to settings. In domestic environments, airborne concentrations may be dramatically low compared with levels reported in occupational settings. OBJECTIVE: Our first objective was therefore to assess the effect of inhalation of low-level lipopolysaccharide (LPS) on the immediate and late-phase asthmatic bronchial response. Our second objective was to evaluate the effect of exposure to LPS on the local and systemic inflammatory response. METHODS: Nineteen asthmatics sensitized to cat underwent on two separate occasions a bronchial challenge test to cat allergen (cat BCT) preceded randomly by a pre-exposure to either saline or LPS (2 microg). Methacholine challenge test was performed 24 h before exposure to LPS or saline. The Borg scale for dyspnoea and lung function were recorded before and after exposure to LPS or saline, and before and after cat BCT. Induced sputum and blood samples were collected before and after cat BCT, and analysed for cell counts and eosinophil cationic protein (ECP) levels. RESULTS: Inhalation of 2 microg LPS did not induce any changes in forced expiratory volume in 1 s (FEV1), peak expiratory flow (PEF), FEF 25-75 and Borg scale of dyspnoea. It neither modified Fel d 1 PD20 (45.03 ng as compared with 87.03; P=0.42). As well, there was no significant difference in late-phase reaction. Pre-exposure to LPS did not influence eosinophil counts or ECP levels in blood and sputum. CONCLUSION: Our study demonstrated that pre-exposure to LPS at low levels, which may be encountered in domestic environment, had no significant effect on the immediate and late-phase bronchial response to cat allergen. It neither modified local and systemic eosinophilic inflammation. 相似文献
152.
153.
Dr. Michele Musci MD H. Siniawski MD PhD C. Knosalla MD PhD O. Grauhan MD PhD Y. Weng MD PhD M. Pasic MD PhD R. Meyer MD PhD R. Hetzer MD PhD 《Clinical research in cardiology》2006,95(5):247-253
Summary
Aims This study investigated the early and mid–term results following valve replacement with the new Shelhigh? stentless bioprosthesis made entirely of biological material in patients with active infective endocarditis (AIE).
Material and methods Between 02/2000 and 12/2004, 164 patients (n = 122 men, mean age 59, 18–85 years) received implantation of an AIE Shelhigh? stentless bioprosthesis in the aortic, mitral, tricuspid or pulmonary position. A total of 119 patients (72.6%) had native
AIE and 45 (27.4%) prosthetic AIE. A large proportion of the patients reached the operating room in a condition of cardiac
decompensation: 37 (22.6%) patients were intubated, 40 (24.4%) had protracted septic shock and 41 (25.0%) required intensive
catecholamine treatment. Surgery was regarded as urgent in 94 patients (57.4%) and was performed as an emergency procedure
in 70 (42.6%). The mean follow–up time is 1.5 ± 0.11 years (range, 5 months to 5.2 years). Echocardiographic follow–up examinations
were performed early postoperatively and after 12 months.
Results In terms of the operative indication, we found a highly significant difference in the survival rate between patients who were
operated on urgently vs in an emergency. In patients who died within 30 days, the main cause of death was septic multiorgan
failure (67.6%). Only three patients required reoperation due to reinfection of the Shelhigh? bioprostheses; this represents a reinfection rate of 1.8% in relation to the whole cohort. The postoperative echocardiographic
examinations showed the Shelhigh? valves to have very good hemodynamics without relevant pressure gradients.
Conclusion Our experience in the use of Shelhigh? bioprostheses in patients with native and prosthetic endocarditis show the early and mid–term results, in particular the
low reinfection rate and the good hemodynamics, to be comparable with the results achieved using homografts. Since these prostheses
are readily available and their implantation straightforward, they are increasingly being used in patients with endocarditis.
These promising results need to verified in the long term.
This paper was presented at a lecture held at the 71st annual meeting of the German Society for Cardiology, Mannheim, 31. March—2. April 2005.
Disclosure Form: The following study discloses my relationship with any corporate sponsor that might relate in some way to
the subject presented. 相似文献
154.
155.
Hellmuth-Alexander Meyer Isabelle Ahrens-Fath Anette Sommer Bernard Haendler 《Biomedicine & Pharmacotherapy》2004,58(1):10-16
Prostate adenocarcinoma is one of the most frequently diagnosed forms of cancer in the male population of the Western world. The pivotal role of androgen and its receptor in this disease has been abundantly documented and indeed, chemical castration and treatment with antiandrogens are now standard therapies. However, relapse is often observed after 18-24 months, due to the remarkable ability of prostate tumour cells to adapt to low or undetectable androgen levels. Amplification and mutations of the androgen receptor (AR) gene have been described as well as alterations in cofactor expression and crosstalk with other signalling pathways. Another recent line of research focused on the re-programming of gene expression taking place in prostate tumours. Global expression profiling of normal and cancerous prostate tissues led to the identification of tumour-distinctive patterns. Validation studies are currently underway to identify novel drug targets as well as diagnostic and outcome prediction markers. 相似文献
156.
Siamak Mohammadi Giuseppe Silvaggio Nicolas Bonnet George Berberian Richard Dorent Marc Bikter Alain Pavie Iradj Gandjbakhch 《The Journal of heart and lung transplantation》2005,24(8):995-997
BACKGROUND: We have noted an unexpectedly high incidence of prostate cancer in our heart transplant recipients (HTR). METHODS: We conducted a retrospective review of patients after heart transplantation to investigate the prevalence, treatment, and outcome of prostate cancer diagnosed after systematic screening (study group). We compared them with case-matched HTR (control). RESULTS: Among 702 recipients, 15 patients had elevated prostate-specific antigen (PSA) levels. Fourteen cases of prostate cancer were diagnosed and treated. The median time between transplantation and prostate cancer diagnosis was 73 months. No patient was diagnosed in a locally advanced (>T2) or metastatic stage. Eleven patients (78.6%) received curative treatment. During follow-up (median, 44 months), 1 patient died from prostate cancer. The survival rate between the study and control groups did not differ. CONCLUSION: Routine PSA testing is recommended as a screening test for prostate cancer in patients after heart transplantation. We believe this could also result in detection of early stages of prostate cancer, thus allowing curative treatment, and achieving similar survival to other case-matched HTR with no prostate cancer. 相似文献
157.
Daniel N. Streblow Craig N. Kreklywich Patricia Smith Jordana L. Soule Christine Meyer Michael Yin Patrick Beisser Cornelis Vink Jay A. Nelson Susan L. Orloff 《American journal of transplantation》2005,5(3):436-442
Cytomegalovirus (CMV) infection accelerates transplant vascular sclerosis (TVS) and chronic rejection (CR) in both human and animal solid organ transplantation models. The host/viral mechanisms involved in this process are unclear. We examine the role of the rat CMV (RCMV)-encoded chemokine-receptor R33 in the development of TVS using a rat heart transplantation/CR model. F344 heart grafts were transplanted heterotopically into Lewis recipients. The ability of RCMV lacking the R33 gene (RCMV-Deltar33) to accelerate CR/TVS (neointimal index, NI) was compared to wild-type (WT) RCMV. Allograft recipients were infected with 1 x 10(5) pfu RCMV or RCMV-Deltar33 on postoperative day (POD) 1. Grafts from RCMV-Deltar33-infected recipients demonstrated an accelerated time to allograft CR compared to grafts from uninfected recipients (POD = 56 vs. 90), this was slower than that seen in grafts from WT-RCMV-infected recipients (POD = 45). Similarly, the degree of graft TVS formation at terminal rejection in RMCV-Deltar33 infected recipients was more severe than uninfected recipients (NI = 63 vs. 45), yet not as severe as in WT-RCMV infected recipients (NI = 83). In parallel, RCMV-Deltar33 failed to induce vascular smooth muscle cell (SMC) migration in vitro, whereas WT-RCMV induced substantial migration. The RCMV-encoded chemokine-receptor r33 is critical for RCMV-accelerated TVS/CR and vascular SMC migration. 相似文献
158.
159.
Jeffrey H Meyer Alan A Wilson Nathalie Ginovart Sylvain Houle 《Neuropsychopharmacology》2007,61(11):1314; author reply 1314-1314; author reply 1315
160.
Prof. Dr. D. Hilfiker-Kleiner T. Selle E. Podewski G.P. Meyer H. Drexler 《Der Kardiologe》2009,3(2):137-145
Peripartum cardiomyopathy (PPCM) is a rare and potentially life-threatening heart disease of unknown etiology that is restricted to the last month of pregnancy and up to 6 months postpartum. The morphology similates that of idiopathic dilated cardiomyopathy with a rapid progression to end-stage heart failure and is associated with a high morbidity and mortality rate. PPCM is treated with standard therapy for heart failure in accordance with the current guidelines. New findings suggest that elevated oxidative stress in the postpartum phase promotes cleavage of the nursing hormone prolactin into a toxic 16-kDa fragment that affects microcirculation and cardiomyocyte metabolism. Thus prolactin blocking using bromocriptine as a more specific therapy option showed promising early clinical results and is currently being tested in larger randomized trials. Frequent symptoms such as general fatigue, dyspnea and dry cough are often misinterpreted as pregnancy-related disturbances, and diagnosis is therefore often late. Interdisciplinary management, early diagnosis and more disease-specific therapy options appear to promote cardiac recovery in PPCM patients. 相似文献